Skip to main content
Top
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Causes of death in patients with extranodal cancer of unknown primary: searching for the primary site

Authors: Matias Riihimäki, Akseli Hemminki, Kristina Sundquist, Kari Hemminki

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Cancer of unknown primary (CUP) is a fatal cancer, accounting for 3–5% of all diagnosed cancers. Finding the primary site is important for therapeutic choices and we believe that the organ which is designated as the cause of death may give clues about the primary site.

Methods

A total of 20,570 patients with CUP were identified from the Swedish Family-Cancer Database. Causes of death – as reported in the death certificate - were investigated, analyzing reported metastatic sites and histological subtypes separately. Survival was compared with metastatic cancer with a known primary tumor.

Results

An organ-specific cancer could be identified as a cause of death in approximately 60% of all CUP patients with adenocarcinoma or undifferentiated histology. In adenocarcinoma, lung cancer was the most frequent cause of death (20%), followed by pancreatic cancer (14%), and ovarian cancer (11%). Lung cancer was the most common cause of death in patients with CUP metastases diagnosed in the nervous system (69%), respiratory system (53%), and bone (47%), whereas ovarian cancer was the most common cause of death when CUP was diagnosed in the pelvis (47%) or the peritoneum (32%). In CUP diagnosed in the liver, liver and pancreatic cancers accounted for 26% and 22% of deaths, respectively. Also in squamous cell CUP, lung cancer was the most common cause of death (45%).

Conclusions

According to the causes of death, the primary site appeared frequently to be either the organ where CUP metastases were diagnosed or an organ which may be traced through the known metastatic patterns of different cancer types.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pentheroudakis G, Briasoulis E, Pavlidis N: Cancer of Unknown Primary Site: Missing Primary or Missing Biology?. Oncologist. 2007, 12 (4): 418-425.CrossRefPubMed Pentheroudakis G, Briasoulis E, Pavlidis N: Cancer of Unknown Primary Site: Missing Primary or Missing Biology?. Oncologist. 2007, 12 (4): 418-425.CrossRefPubMed
2.
go back to reference Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G: Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011, 22 (6): vi64-vi68.PubMed Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G: Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011, 22 (6): vi64-vi68.PubMed
3.
4.
go back to reference Hemminki K, Ji J, Sundquist J, Shu X: Familial risks in cancer of unknown primary: tracking the primary sites. J Clin Oncol. 2011, 29 (4): 435-440.CrossRefPubMed Hemminki K, Ji J, Sundquist J, Shu X: Familial risks in cancer of unknown primary: tracking the primary sites. J Clin Oncol. 2011, 29 (4): 435-440.CrossRefPubMed
5.
go back to reference Hemminki K, Bevier M, Sundquist J, Hemminki A: Cancer of unknown primary (CUP): does cause of death and family history implicate hidden phenotypically changed primaries?. Ann Oncol. 2012, 23 (10): 2720-2724.CrossRefPubMed Hemminki K, Bevier M, Sundquist J, Hemminki A: Cancer of unknown primary (CUP): does cause of death and family history implicate hidden phenotypically changed primaries?. Ann Oncol. 2012, 23 (10): 2720-2724.CrossRefPubMed
6.
go back to reference Levi F, Te V, Erler G, Randimbison L, La Vecchia C: Epidemiology of unknown primary tumours. Eur J Cancer. 2002, 38: 1810-1812.CrossRefPubMed Levi F, Te V, Erler G, Randimbison L, La Vecchia C: Epidemiology of unknown primary tumours. Eur J Cancer. 2002, 38: 1810-1812.CrossRefPubMed
7.
go back to reference van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF: Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984–1992. Eur J Cancer. 2002, 38 (3): 409-413.CrossRefPubMed van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF: Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984–1992. Eur J Cancer. 2002, 38 (3): 409-413.CrossRefPubMed
8.
go back to reference Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL: Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res. 1999, 5 (11): 3403-3410.PubMed Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL: Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res. 1999, 5 (11): 3403-3410.PubMed
9.
go back to reference Hemminki K, Bevier M, Hemminki A, Sundquist J: Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol. 2012, 23 (7): 1854-1863.CrossRefPubMed Hemminki K, Bevier M, Hemminki A, Sundquist J: Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol. 2012, 23 (7): 1854-1863.CrossRefPubMed
10.
go back to reference Lazaridis G, Pentheroudakis G, Fountzilas G, Pavlidis N: Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev. 2008, 34 (8): 693-700.CrossRefPubMed Lazaridis G, Pentheroudakis G, Fountzilas G, Pavlidis N: Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev. 2008, 34 (8): 693-700.CrossRefPubMed
11.
go back to reference Riihimäki M, Thomsen H, Hemminki A, Sundquist K, Hemminki K: Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer. BMC Cancer. 2013, 13: 36-CrossRefPubMedPubMedCentral Riihimäki M, Thomsen H, Hemminki A, Sundquist K, Hemminki K: Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer. BMC Cancer. 2013, 13: 36-CrossRefPubMedPubMedCentral
12.
go back to reference Hemminki K, Riihimaki M, Sundquist K, Hemminki A: Site-specific survival rates for cancer of unknown primary according to location of metastases. Int J Cancer. 2013, 133: 182-189.CrossRefPubMed Hemminki K, Riihimaki M, Sundquist K, Hemminki A: Site-specific survival rates for cancer of unknown primary according to location of metastases. Int J Cancer. 2013, 133: 182-189.CrossRefPubMed
13.
go back to reference Pentheroudakis G, Greco FA, Pavlidis N: Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review. Cancer Treat Rev. 2009, 35 (3): 221-227.CrossRefPubMed Pentheroudakis G, Greco FA, Pavlidis N: Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review. Cancer Treat Rev. 2009, 35 (3): 221-227.CrossRefPubMed
14.
go back to reference Pentheroudakis G, Golfinopoulos V, Pavlidis N: Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer. 2007, 43 (14): 2026-2036.CrossRefPubMed Pentheroudakis G, Golfinopoulos V, Pavlidis N: Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer. 2007, 43 (14): 2026-2036.CrossRefPubMed
15.
go back to reference Kwee TC, Kwee RM: Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2009, 19 (3): 731-744.CrossRefPubMed Kwee TC, Kwee RM: Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2009, 19 (3): 731-744.CrossRefPubMed
16.
go back to reference Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, Greco FA: Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013, 31 (2): 217-223.CrossRefPubMed Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, Greco FA: Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013, 31 (2): 217-223.CrossRefPubMed
17.
go back to reference Stella G, Senetta R, Cassenti A, Ronco M, Cassoni P: Cancers of unknown primary origin: current perspectives and future therapeutic strategies. J Transl Med. 2012, 10 (1): 12-CrossRefPubMedPubMedCentral Stella G, Senetta R, Cassenti A, Ronco M, Cassoni P: Cancers of unknown primary origin: current perspectives and future therapeutic strategies. J Transl Med. 2012, 10 (1): 12-CrossRefPubMedPubMedCentral
18.
go back to reference Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N: Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer. 2005, 5 (1): 25-CrossRefPubMedPubMedCentral Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N: Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer. 2005, 5 (1): 25-CrossRefPubMedPubMedCentral
19.
go back to reference Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N: Matrix metalloproteinases in carcinoma of unknown primary. Cancer. 2005, 104 (10): 2282-2287.CrossRefPubMed Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N: Matrix metalloproteinases in carcinoma of unknown primary. Cancer. 2005, 104 (10): 2282-2287.CrossRefPubMed
20.
go back to reference Shu X, Sundquist K, Sundquist J, Hemminki K: Time trends in incidence, causes of death, and survival of cancer of unknown primary in Sweden. Eur J Cancer Prev. 2012, 21 (3): 281-288.CrossRefPubMed Shu X, Sundquist K, Sundquist J, Hemminki K: Time trends in incidence, causes of death, and survival of cancer of unknown primary in Sweden. Eur J Cancer Prev. 2012, 21 (3): 281-288.CrossRefPubMed
21.
go back to reference Hemminki K, Bevier M, Sundquist J, Hemminki A: Site-specific cancer deaths in cancer of unknown primary diagnosed with lymph node metastasis may reveal hidden primaries. Int J Cancer. 2013, 132 (4): 944-950.CrossRefPubMed Hemminki K, Bevier M, Sundquist J, Hemminki A: Site-specific cancer deaths in cancer of unknown primary diagnosed with lymph node metastasis may reveal hidden primaries. Int J Cancer. 2013, 132 (4): 944-950.CrossRefPubMed
22.
go back to reference Hemminki K, Ji J, Brandt A, Mousavi SM, Sundquist J: The Swedish Family-Cancer Database 2009: prospects for histology-specific and immigrant studies. Int J Cancer. 2010, 126 (10): 2259-2267.PubMed Hemminki K, Ji J, Brandt A, Mousavi SM, Sundquist J: The Swedish Family-Cancer Database 2009: prospects for histology-specific and immigrant studies. Int J Cancer. 2010, 126 (10): 2259-2267.PubMed
23.
go back to reference Shu X, Liu H, Ji J, Sundquist K, Forsti A, Sundquist J, Hemminki K: Subsequent cancers in patients diagnosed with cancer of unknown primary (CUP): etiological insights?. Ann Oncol. 2012, 23 (1): 269-275.CrossRefPubMed Shu X, Liu H, Ji J, Sundquist K, Forsti A, Sundquist J, Hemminki K: Subsequent cancers in patients diagnosed with cancer of unknown primary (CUP): etiological insights?. Ann Oncol. 2012, 23 (1): 269-275.CrossRefPubMed
24.
go back to reference Ji J, Sundquist K, Sundquist J, Hemminki K: Comparability of cancer identification among Death Registry, Cancer Registry and Hospital Discharge Registry. Int J Cancer. 2012, 131 (9): 2085-2093.CrossRefPubMed Ji J, Sundquist K, Sundquist J, Hemminki K: Comparability of cancer identification among Death Registry, Cancer Registry and Hospital Discharge Registry. Int J Cancer. 2012, 131 (9): 2085-2093.CrossRefPubMed
25.
go back to reference Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL: Metastatic patterns in adenocarcinoma. Cancer. 2006, 106 (7): 1624-1633.CrossRefPubMed Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL: Metastatic patterns in adenocarcinoma. Cancer. 2006, 106 (7): 1624-1633.CrossRefPubMed
26.
go back to reference Chen LL, Blumm N, Christakis NA, Barabasi AL, Deisboeck TS: Cancer metastasis networks and the prediction of progression patterns. Br J Cancer. 2009, 101 (5): 749-758.CrossRefPubMedPubMedCentral Chen LL, Blumm N, Christakis NA, Barabasi AL, Deisboeck TS: Cancer metastasis networks and the prediction of progression patterns. Br J Cancer. 2009, 101 (5): 749-758.CrossRefPubMedPubMedCentral
27.
go back to reference Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002, 2 (8): 584-593.CrossRefPubMed Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002, 2 (8): 584-593.CrossRefPubMed
29.
go back to reference Langley RR, Fidler IJ: The seed and soil hypothesis revisited-The role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. 2011, 128 (11): 2527-2535.CrossRefPubMedPubMedCentral Langley RR, Fidler IJ: The seed and soil hypothesis revisited-The role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. 2011, 128 (11): 2527-2535.CrossRefPubMedPubMedCentral
30.
go back to reference Randen M, Rutqvist L-E, Johansson H: Cancer patients without a known primary: Incidence and survival trends in Sweden 1960–2007. Acta Oncologica. 2009, 48 (6): 915-920.CrossRefPubMed Randen M, Rutqvist L-E, Johansson H: Cancer patients without a known primary: Incidence and survival trends in Sweden 1960–2007. Acta Oncologica. 2009, 48 (6): 915-920.CrossRefPubMed
Metadata
Title
Causes of death in patients with extranodal cancer of unknown primary: searching for the primary site
Authors
Matias Riihimäki
Akseli Hemminki
Kristina Sundquist
Kari Hemminki
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-439

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine